NewEdge Advisors’s Medifast MED Stock Holding History

NewEdge Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-22	Closed	-$297	–	4090
2025 Q1	$297	Buy	+22	New	+$330	﹤0.01%	3771
2023 Q1	–	Sell	-4	Closed	-$461	–	3861
2022 Q4	$461	Buy	+4	New	+$466	﹤0.01%	3185

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NewEdge Advisors's MED Position: Q2 2025 in Review

NewEdge Advisors sold out of Medifast (MED) in Q2 2025, closing a stake of 22 shares — an estimated $297 sold.

NewEdge Advisors first reported a position in MED in Q4 2022 and held it in 2 quarters. The position peaked at $461 in Q4 2022. 120 funds tracked by Wall St. Rank hold MED as of Q2 2025.

NewEdge Advisors reported no remaining Medifast position as of Q2 2025 after selling out during the quarter.
NewEdge Advisors sold 22 Medifast shares in Q2 2025, an estimated $297.
NewEdge Advisors first reported a position in Medifast in Q4 2022 and held it in 2 quarters.
NewEdge Advisors's Medifast position peaked at $461 in Q4 2022.
120 funds tracked by Wall St. Rank held Medifast as of Q2 2025.

Based on NewEdge Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.